Home › Funds › Samsara BioCapital, LLC › ABVX
Samsara BioCapital, LLC position in ABVX
ABIVAX SA · Health Care
Samsara BioCapital, LLC reported holding 55,095 shares of ABVX (ABIVAX SA) in its Q3 2026 13F filing — a position valued at US$5.5M, representing 0.52% of its reported portfolio and ranking #22 among its reported holdings. Samsara BioCapital, LLC has disclosed ABVX holdings in 11 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Samsara BioCapital, LLC's ABVX position evolved
Samsara BioCapital, LLC first disclosed a stake in ABVX in Q4 2023 at 850,000 shares (US$9.1M). The position peaked in Q1 2024 at 850,000 shares, worth US$12.2M. Across 11 filings, Samsara BioCapital, LLC increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 55,095 shares valued at US$5.5M. Notable position changes include a 50% trim in Q1 2025 (shares rose 22% over the following quarter), a 25% trim in Q1 2026 (shares rose 20% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 850.00K | $9.10M | New |
| Q1 2024 | 850.00K | $12.15M | Hold |
| Q2 2024 | 850.00K | $11.24M | Hold |
| Q3 2024 | 850.00K | $9.79M | Hold |
| Q4 2024 | 850.00K | $6.22M | Hold |
| Q1 2025 | 425.00K | $2.66M | Reduce |
| Q3 2025 | 75.44K | $6.41M | New |
| Q4 2025 | 75.44K | $10.17M | Hold |
| Q1 2026 | 56.58K | $6.30M | Reduce |
| Q2 2026 | 55.09K | $7.34M | Reduce |
| Q3 2026 | 55.09K | $5.46M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABVX and 13F data
ABVX (ABIVAX SA) is a Health Care company. 58 other funds we track also report a position in ABVX — the largest reported positions include Helikon Investments Ltd (US$418.2M), Darwin Global Management, Ltd. (US$398.2M), Vestal Point Capital, LP (US$392.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABVX
- Helikon Investments Ltd 4.22M sh · $418.15M · Q3 2026
- Darwin Global Management, Ltd. 4.02M sh · $398.22M · Q3 2026
- Vestal Point Capital, LP 3.96M sh · $392.12M · Q3 2026
- TCG Crossover Management, LLC 3.66M sh · $362.71M · Q3 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 1.65M sh · $163.56M · Q3 2026
- Caligan Partners LP 1.56M sh · $154.27M · Q3 2026
- Eversept Partners, LP 1.10M sh · $108.99M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 1.03M sh · $102.00M · Q3 2026
- Octagon Capital Advisors LP 993.00K sh · $98.33M · Q3 2026
- Logos Global Management LP 870.00K sh · $86.15M · Q3 2026
- Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. 762.82K sh · $75.53M · Q3 2026
- Two Seas Capital LP 676.59K sh · $67.00M · Q3 2026
More on Samsara BioCapital, LLC
FAQ
How long has Samsara BioCapital, LLC held ABVX?
Samsara BioCapital, LLC has disclosed ABVX holdings in 11 of the last 12 reported quarters, going back to Q4 2023.
What is Samsara BioCapital, LLC's current position in ABVX?
As of Q3 2026, Samsara BioCapital, LLC holds 55.09K shares of ABVX (ABIVAX SA), valued at $5.46M, representing 0.52% of its reported portfolio and ranking #22.
Has Samsara BioCapital, LLC been buying or selling ABVX?
In the latest 13F filing (Q3 2026), Samsara BioCapital, LLC held unchanged its position in ABVX. The position peaked in Q1 2024 at 850.00K shares.
Which other funds hold ABVX?
Other major institutional holders of ABVX include Helikon Investments Ltd, Darwin Global Management, Ltd., Vestal Point Capital, LP, among 58 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.